BMS-707035

• CAT Number: I004717
• CAS Number: 729607-74-3
• Molecular Formula: C17H19FN4O5S
• Molecular Weight: 410.40
• Purity: ≥95%
• Synonyms: 2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide
• Target: Metabolic Enzyme/Protease
• Solubility: 10 mM in DMSO
• Storage: 3 years -20℃ powder
• IC50: 15 nM
• InChI: InChI=1S/C17H19FN4O5S/c1-21-16(25)14(23)13(15(24)19-10-11-4-6-12(18)7-5-11)20-17(21)22-8-2-3-9-28(22,26)27/h4-7,23H,2-3,8-10H2,1H3,(H,19,24)
• InChIKey: VNIWZCGZPBJWBI-UHFFFAOYSA-N
• SMILES: CN1C(=O)C(=C(N=C1N2CCCCS2(=O)=O)C(=O)NCC3=CC=C(C=C3)F)O

BMS-707035（Cat No.:I004717）is a potent and selective inhibitor of HIV-1 integrase, a key enzyme required for the integration of viral DNA into the host genome during the replication cycle. By targeting the strand transfer step, BMS-707035 effectively halts viral replication. It exhibits strong activity against HIV-1 and retains efficacy against various drug-resistant strains, making it a valuable candidate for antiretroviral therapy. With favorable pharmacokinetics and a high barrier to resistance, BMS-707035 holds promise in developing new therapeutic strategies to combat HIV and improve patient outcomes.

Reference

[1]. Cotelle P.,3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.,Expert Opin Ther Pat. 2011 Nov;21(11):1799-804.
[2]. Al-Mawsawi LQ, Al-Safi RI, Neamati N.,Anti-infectives: clinical progress of HIV-1 integrase inhibitors.,Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25.
[3]. Dayam R, Al-Mawsawi LQ, Neamati N.,HIV-1 integrase inhibitors: an emerging clinical reality.,Drugs R D. 2007;8(3):155-68.
[4]. Dicker IB, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem. 2007 Oct 26;282(43):31186-96.